CAPhO 2024 Sponsored Symposium Janssen - Patient Management Considerations for Bispecific Antibodies for Multiple Myeloma in Canada and the Role of the Pharmacist

This interactive symposium will feature a panel of experts providing guidance and real-world perspectives exploring the emerging role for T-cell redirecting therapies, particularly bispecifics, in the management of relapsed/refractory Multiple Myeloma within the Canadian clinical setting. 

Learning Objectives:

• Establish the emerging role for T-cell redirecting therapies in the management of relapsed/refractory Multiple Myeloma (RRMM) in Canada
• Identify key safety management considerations for bispecific antibodies for Multiple Myeloma to optimize the patient journey and inform appropriate patient selection
• Consider the role of the pharmacist to support patient management throughout the delivery of bispecific antibodies for Multiple Myeloma within the Canadian setting

Sponsored by Janssen